Navigation Links
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent, Implantation of Multiple Stents and Small Vessel Size To Be Independent Predictors of Need for Another Procedure


MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark Heart Registry found that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent to open a clogged artery were less likely to need another procedure at that same lesion site (a clinical event called target lesion revascularization or TLR) than patients who received a Taxus Stent. The analysis was published in the June 1 issue of the journal Heart.

The authors of the analysis sought to identify risk factors for symptom- driven TLR when patients were treated with the CYPHER(R) Stent or the Taxus Stent in a real-world scenario. From Jan. 1, 2003 to May 18, 2005, 4,432 patients in Western Denmark were treated with a drug-eluting stent (CYPHER(R) Stent: 2,728 patients; Taxus Stent: 1,704 patients). Use of a Taxus Stent (odds ratio of 1.43; p=0.022), implantation of multiple stents per lesion (odds ratio of 1.62; p=0.008) and stent implantation in small vessels (odds ratio of 1.42; p=0.049) were found to be independent predictors of the need for TLR at nine months after the procedure.

"The major new finding of this study was that the use of the Taxus Stent was an independent predictor of TLR for a real-world population of patients treated with the CYPHER(R) Stent and the Taxus Stent," said Michael Maeng, M.D., Principal Investigator, from Aarhus University Hospital, Denmark.

When the lesions were divided into subgroups according to vessel size, the CYPHER(R) Stent yielded a 20 percent relative reduction of TLR in large vessels (2.4 percent versus 3.0 percent in arteries with a reference diameter equal to or greater than 2.8 mm; p=not significant) and a 40 percent relative reductio
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
(Date:9/29/2014)... Sept. 29, 2014  Bob Pack, who lost his ... on the California Medical Association to immediately cease airing ... the San Jose Mercury News called "shamelessly deceptive" and ... wants voters to believe about the measure is wrong." ... Prop 46 requirement that doctors check California,s ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... Computer Resources of America, Inc. ... in New York City, has been awarded a ... transform, manage, and support the IT environment of ... leading provider of innovative services that enable individuals ... The contract will cover the four NY-metro locations ...
(Date:9/30/2014)... All on Four dental implants ... have received dental implants to vigilant in the fight ... The post, which can be found at http://www.newalbanyimplants.com/dr-rons-blog/ ... don’t brush and floss diligently, they could lose their ... teeth: the bone will deteriorate and the implants will ...
(Date:9/30/2014)... Ontario, Canada (PRWEB) September 30, 2014 ... diagnostic imaging services based in San Juan, Puerto ... automate their workflows. , Nivia Souffront, site ... to their facility. “We are excited to bring ... to provide better patient care and physician satisfaction ...
(Date:9/30/2014)... Westminster, Maryland (PRWEB) September 30, 2014 3M ... of acrylic very high bond tapes. 3M 5906 , ... 3M 5909 are conformable VHBs which help create the ... acrylic foam tapes are used for bonding to difficult surfaces ... , 3M VHBs 5906, 5907, 5908, and 5905 are designed ...
(Date:9/30/2014)... Doctors often order breast ultrasounds as a ... Most breast ultrasounds are done at a specialized medical imaging ... Miami . The Center for Diagnostic Imaging is now ... Most patients find ultrasounds to be more comfortable as ... have to remain perfectly still. , “We realize ...
Breaking Medicine News(10 mins):Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Breast Ultrasounds Are a Comfortable and Convenient Option for Patients and Referring Doctors 2
... help medicine go down , , ... medicine go down" -- parents know in reality it just isn,t ... -- unique, frozen single-use packages that offer cooling, soothing relief to ... , Sucrets ICE is the newest member ...
... the definitive online resource for women who want to look fabulous ... Zuckerbrot, M.S., R.D., has assembled the most credited team of experts ... them all together on one website to offer the most on-trend, ... no cost and no calories to the consumer. , ...
... first 3 months more likely to have respiratory woes , , ... folic acid (folate) during early pregnancy may have an increased ... Folate is recommended to reduce the risk of birth defects, ... The researchers examined data on more than 32,000 children born ...
... behavior and screening have contributed greatly to the 13 percent ... playing a supporting role, according to new research from David ... first to report a long-term decline in cancer mortality, Cutler,s ... decline. Published in the fall edition of the Journal ...
... News/ -- EIN News has announced the launch of a new ... , With new advances in medicine, more and ... key components to surviving cancer. , ... about prostate cancer, its risk factors, screening procedures and drugs to ...
... Southern Research Institute -- a not-for-profit scientific organization that conducts ... discovery and development, advanced engineering, environmental and energy production -- ... Black & Veatch to help support the U.S. Department of ... , The award is expected ...
Cached Medicine News:Health News:New Sucrets(R) ICE Cools Sore Throat Pain 2Health News:SkinnyAndTheCity.com Top Experts Create the Ultimate Lifestyle Guide 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:Drop in cancer deaths tied primarily to gains in behavior and screening 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: